Loading
A phase 2 trial of Belzutifan in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) is a phase 2 interventional study registered as NCT04489771 by Merck Sharp & Dohme LLC, with 154 participants enrolled, started 2020-09-13 and due to reach its primary completion in 2023-02-10. Interventions recorded: Belzutifan. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
154 enrolled.
95% CI 14.3 to 34.0; Figures from the ClinicalTrials.gov results section (first posted 2024-02-28), not from a publication · 95% CI 14.7 to 34.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)primary | Belzutifan 200 mg | 78 | 23.1% | - | 0.5312 | link |
| Belzutifan 120 mg | 76 | 23.7% |
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors.